Propanc Biopharma, Inc.

Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing effective medicines for chronic diseases, particularly cancer. The company's mission is to provide unique, effective treatments with lasting benefits and minimal side effects for patients globally. Headquartered in Camberwell, Victoria, Australia, Propanc Biopharma focuses on addressing the challenges of recurrent and metastatic solid tumors.

Propanc Biopharma's primary product candidate is PRP, a novel, patented formulation comprising two pancreatic proenzymes, trypsinogen and chymotrypsinogen, administered via intravenous injection. This therapy is designed to prevent tumor recurrence and metastasis by controlling cancer cell migration, inhibiting tumor blood vessel formation, and triggering cell death. The company initially targets pancreatic, ovarian, and colorectal cancers and is also developing a fully synthetic backup compound, Rec-PRP.

Propanc Biopharma uplisted to the Nasdaq stock exchange in August 2025. The company is advancing its lead candidate, PRP, into a Phase Ib study in 2026, targeting 30-40 advanced cancer patients with malignant solid tumors at the Peter MacCallum Cancer Centre in Melbourne, Australia. James Nathanielsz serves as the CEO, a position he has held since October 2007. In a strategic move to diversify its asset base, Propanc Biopharma announced in November 2025 its intention to acquire Digital Asset Treasury (DAT) companies while continuing to develop its oncology pipeline. The company holds a robust intellectual property portfolio, with over 90 patents filed globally for its PRP technology.